Tara Golisch
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Tara Golisch as PDF for free.
More details
- Words: 282
- Pages: 21
Efficacy of ranibizumab in eyes with significant hemorrhage from neovascular AMD Tara Golisch, BS Josh Robinson, MD Jonathan L. Prenner, MD
Financial Disclosures •Consultant •Opko •Ophthotech •Neovista •Alcon •J&J •Genentech
Background: •Most AMD trials exclude eyes with >50% blood •No prospective evidence to guide management in these eyes
Background: •Some eyes likely require surgical intervention •Massive hemorrhage •Significant breakthrough bleeding •What should the approach be in eyes with less severe hemorrhages?
Is anti-VEGF therapy effective in eyes like these?
Hypothesis: •Eyes with >50% hemorrhage may do well with anti-VEGF therapy •Examine the efficacy of ranibizumab in these less well studied eyes
Methods: •Retrospective review •29 eyes of 29 patients •Presented with CNV complexes that had >50% blood •Treatment naive •Monotherapy with ranibizumab
Methods: •Fifty five percent were taking anticoagulation
Methods: •All patients had •Three injections of ranibizumab •Fifteen weeks of follow up •Baseline and 15 week FA •Allowed for measurement of lesions and subsequent analysis
Methods: •Endpoints •Anatomic: amount of blood resolution •Functional: change in snellen visual acuity
Baseline:
Week 15:
Baseline:
Week 15:
Results:
Results: blood composition •Baseline •77.6% blood •Range 51-100% •Week 15 •9.5% blood •Range 0-50%
Results: visual acuity •Baseline •20/200 -1 •Range (CF to 20/30) •Week 15 •20/200 +2 •Range (CF to 20/25)
Results: visual acuity •Three line gainers: 34% •Non responders: 7%
No Change Lost > 3 lines Gained <3 lines
Lost <3 lines Gaines >3 lines
Conclusions: •This cohort of eyes typically excluded in clinical trials responded well •Anatomically: most eyes had significant blood resolution •Functionally: visual data mirrored large prospective trials
Conclusions: •Anti-VEGF monotherapy seems reasonable in this cohort of patients •Prognosis seems better than might be expected in these less well studied eyes
Mahalo
Financial Disclosures •Consultant •Opko •Ophthotech •Neovista •Alcon •J&J •Genentech
Background: •Most AMD trials exclude eyes with >50% blood •No prospective evidence to guide management in these eyes
Background: •Some eyes likely require surgical intervention •Massive hemorrhage •Significant breakthrough bleeding •What should the approach be in eyes with less severe hemorrhages?
Is anti-VEGF therapy effective in eyes like these?
Hypothesis: •Eyes with >50% hemorrhage may do well with anti-VEGF therapy •Examine the efficacy of ranibizumab in these less well studied eyes
Methods: •Retrospective review •29 eyes of 29 patients •Presented with CNV complexes that had >50% blood •Treatment naive •Monotherapy with ranibizumab
Methods: •Fifty five percent were taking anticoagulation
Methods: •All patients had •Three injections of ranibizumab •Fifteen weeks of follow up •Baseline and 15 week FA •Allowed for measurement of lesions and subsequent analysis
Methods: •Endpoints •Anatomic: amount of blood resolution •Functional: change in snellen visual acuity
Baseline:
Week 15:
Baseline:
Week 15:
Results:
Results: blood composition •Baseline •77.6% blood •Range 51-100% •Week 15 •9.5% blood •Range 0-50%
Results: visual acuity •Baseline •20/200 -1 •Range (CF to 20/30) •Week 15 •20/200 +2 •Range (CF to 20/25)
Results: visual acuity •Three line gainers: 34% •Non responders: 7%
No Change Lost > 3 lines Gained <3 lines
Lost <3 lines Gaines >3 lines
Conclusions: •This cohort of eyes typically excluded in clinical trials responded well •Anatomically: most eyes had significant blood resolution •Functionally: visual data mirrored large prospective trials
Conclusions: •Anti-VEGF monotherapy seems reasonable in this cohort of patients •Prognosis seems better than might be expected in these less well studied eyes
Mahalo
Related Documents
Tara Golisch
November 2019 11
Tara
May 2020 26
Tara Portfolio
June 2020 11
Tara Romaneasca
October 2019 33
Tara Fagaduintei
April 2020 14